Cantor Fitzgerald lowered the firm’s price target on Artiva Biotherapeutics (ARTV) to $20 from $23 and keeps an Overweight rating on the shares. The firm notes a “healthy amount of enthusiasm” from rheumatology specialists that cell therapy has the potential to deliver durable drug-free remissions for patients in a way that hasn’t been achieved previously, though Cantor acknowledges “it’s not the best time” to be a cell therapy for autoimmune disorders stock given concerns about competitive dynamics and slow cadence of enrollment. Cantor tells investors in a research note that it “eagerly” awaits the company’s Q2 data update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue